Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing
Biomarker testing is key to unlocking precision medicine. However, coverage for guideline-recommended biomarker tests is not universal and can be a barrier to cancer patients accessing treatments that can lead to improved survival and quality of life.